Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 23, 2023
Deals

Persistence, creative combinations behind Karuna’s $14B exit

BMS acquires Karuna, brightening the spotlight on schizophrenia, muscarinic receptors and neurology
BioCentury | May 13, 2021
Product Development

May 12 Quick Takes: Biogen-TMS in stroke deal; plus Minerva, Autobahn-Astellas, Emergent, Magenta, Fosun-BioNTech 

Biogen Inc. (NASDAQ:BIIB) is exercising an option to acquire a next-generation thrombolytic agent from TMS Co. Ltd. The move comes after the Japanese company showed TMS-007 reopened blood vessels and
BioCentury | Oct 27, 2020
Product Development

Oct. 26 Quick Takes: COVID trips up Spectrum’s Rolontis at FDA; plus Jazz-SpringWorks, Novartis’ iptacopan, Kantaro, Eternygen

Delay for Spectrum due to COVID-19 travel restrictionsSpectrum Pharmaceuticals Inc. (NASDAQ:SPPI) said FDA is deferring action on the company’s BLA for its Rolontis eflapegrastim because the
BioCentury | Jun 10, 2020
Emerging Company Profile

Autobahn: fine-tuning thyroid agonism to remyelinate axons

Arch-incubated remyelination play Autobahn launches with $76M series B
BioCentury | Aug 2, 2018
Tools & Techniques

Model firsts

How quantitative systems pharmacology can pick the right dose for first-in-human trials
BioCentury | Sep 29, 2017
Financial News

SpringWorks launches with $103M series A

BioCentury | Sep 29, 2017
Finance

Spring cleaning

SpringWorks provides a development path for pharma's de-prioritized assets
BioCentury | Sep 25, 2017
Financial News

SpringWorks launches with $103M series A

Items per page:
1 - 10 of 77